Real-world use of inhaled treprostinil for lung disease-pulmonary hypertension: A protocol for patient evaluation and prescribing.
Shelsey W JohnsonLauren FinlayStephen C MathaiRonald H GoldsteinBradley A MaronPublished in: Pulmonary circulation (2022)
Inhaled treprostinil was approved recently for interstitial lung disease-pulmonary hypertension; however, efficacy in "real-world" populations is not known. We designed a protocol and report our experience evaluating 10 patients referred for therapy. Misdiagnosis at presentation was common; ultimately, three patients (30%) were prescribed drug. This protocol offers an opportunity to standardize longitudinal assessment of inhaled treprostinil in clinical practice.
Keyphrases
- pulmonary hypertension
- end stage renal disease
- pulmonary arterial hypertension
- randomized controlled trial
- interstitial lung disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- clinical practice
- systemic sclerosis
- cystic fibrosis
- primary care
- prognostic factors
- rheumatoid arthritis
- stem cells
- pulmonary artery
- emergency department
- coronary artery
- bone marrow
- mesenchymal stem cells
- adverse drug
- smoking cessation